WilliamHSharfmanMD

Hematologic Oncology, Melanoma

Associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine Director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program.

Join to view full profile

Dr. Sharfman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sharfman's full profile

Already have an account?

Office
10803 Falls Road
Pavilion III STE 1500
Lutherville, MD 21093
Phone+1 410-583-2970

Fax+1 410-583-2980

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1986 - 1989
Cleveland Clinic FoundationResidency, Internal Medicine, 1982 - 1985
The University of Toledo College of MedicineClass of 1982

Certifications & Licensure

DE State Medical License Current
MD State Medical License 1989 - 2025
FL State Medical License 2020 - 2022
PA State Medical License 2020 - 2022
OH State Medical License 1985 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Start of enrollment: 1999 Feb 01
Completed
Phase 2
Melanoma Biomarker Study Start of enrollment: 2006 May 01
Completed
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01
Terminated
Phase 4
Join now to see all

Publications & Presentations

PubMed

Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II...
Shailender Bhatia, Suzanne L Topalian, William Sharfman, Tim Meyer, Neil Steven
Journal of Clinical Oncology. 2025-03-20
3 citations
Immune-related encephalitis after immune checkpoint inhibitor therapy.
Monica W Buckley, Aanika Balaji Warner, Julie Brahmer, Laura C Cappelli, William H Sharfman
The Oncologist. 2025-01-17
15 citations
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
Ana Oaknin, Kathleen Moore, Tim Meyer, José López-Picazo González, Lot A Devriese
The Lancet. Oncology. 2024-05-01

Journal Articles

From Validity to Clinical Utility: The Influence of Circulating Tumor DNA on Melanoma Patient Management in a Real‐World Setting
Karen B Bleich, William H Sharfman, Steven P Rowe, Evan J Lipson, Megan D Schollenberger, Molecular Oncology

Press Mentions

Tip Sheet: Johns Hopkins Kimmel Cancer Center Researchers to Present at Asco Annual MeetingMay 26th, 2023
Miller-Coulson Academy Induction Set for April 17March 8th, 2017
Melanoma: Immunotherapy-Induced Vitiligo Documented as Linked to Better OutcomesMay 25th, 2015
Join now to see all